Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

Rethinking Chronic Multinodular Interstitial Disease in a 70-year-old Woman: A Case of Diffuse Pulmonary Meningotheliomatosis
Walton, Nick , Manchen, Peter , Filsoof, Darius, Chaudhary, Sachin , Walton, N.T.

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A7500-A7500

10.1164/ajrccm.2025.211.abstracts.a7500 Get It

Abstract Background: Diffuse pulmonary meningotheliomatosis (DPM) is a rare, benign proliferation of minute meningothelial-like nodules ranging from 100mm – 11mm.1 The condition presents primarily in women (9:1) in middle age.2 Discovered incidentally or with mild symptoms such as dyspnea and dry cough, the imaging findings can be concerning for miliary metastatic, atypical infectious, and immune mediated diffuse parenchymal lung disease thereby complicating the diagnostic process. Case Description: A 70-year-old female never smoker presented to our pulmonary clinic for evaluation of dyspnea and dry cough. She described evaluation roughly 20 years prior that had revealed innumerable small ground glass pulmonary nodules on CT imaging. Pulmonary function testing at that time was unremarkable, and laboratory studies had only revealed a weakly (+) SSA antibody. She was referred for a right mini-thoracotomy wedge resection, with pathology demonstrating small nodules partially involving the pleura, suspected to represent hypersensitivity pneumonitis (HP), as well as, several incidentally noted pulmonary “chemodectomas”. She was trialed on inhaled therapies, antibiotics, and even a two-year course of steroids for suspected HP without notable clinical or radiologic improvement. Interestingly, she was subsequently found to have an intracranial meningioma which was treated with external beam radiation. Upon presentation at our institution, a repeat high resolution chest CT showed mosaic attenuation with innumerable groundglass nodules and micronodules in a centrilobular and peri-lymphatic distribution. There was no significant change in appearance or distribution from prior imaging (Figure 1, A-B). Rigid bronchoscopy with transbronchial lung cryobiopsy was performed with pathology showing multiple meningothelial-like nodules (Figure 1, C). This pathologic finding, in conjunction with her clinical history, including past surgical biopsy, led to a diagnosis of DPM. Discussion: This case adds to about 50 cases of DPM and the clinical significance of diffuse perivenular and interstitial meningothelial-like cell proliferations in the lung without clear malignant potential. Additionally, it provides another case to a notable collection of cases with metachronous intracranial meningioma, suggesting possible shared pathogenesis or genetic predisposition.2 While the clinical course of DPM is generally indolent, it poses diagnostic challenges due to overlapping imaging characteristics with more aggressive pulmonary pathologies. The differential may include sarcoidosis, miliary infectious and malignant etiologies, DIPNECH, and follicular bronchiolitis. Conclusions: A systematic approach to this patient's ground-glass nodules with clinical re-evaluation given ineffective empiric treatment ultimately led to the correct diagnosis. It highlights the importance of biopsy for the diagnosis of pulmonary nodules of unclear etiology even with benign clinical progression.
Constrictive Bronchiolitis With Paraneoplastic Autoimmune Multi-organ Syndrome Treated With Lung Transplantation
Mokahal, Ali El , Pennington, Kelly M. , Porquera, Eva M. Carmona, Kanj, A.N.

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A7495-A7495

10.1164/ajrccm.2025.211.abstracts.a7495 Get It

Abstract Introduction: We present a case of constrictive bronchiolitis with paraneoplastic autoimmune multi-organ syndrome (PAMS) treated with lung transplantation. To our knowledge, this is the first reported case of PAMS with constrictive bronchiolitis managed with this approach. Presentation: A 45-year-old woman presented with 3 months of dyspnea. PFTs showed severe airflow obstruction with air trapping and no immediate bronchodilator response. [FEV1 0.94L (z: -3.9), FVC 2.98L (z: -0.515), TLC 4.89L (z: 1.0), RV 1.70L (z: 2.4) and DLCO 22 ml/min/mmhg (z: 0.58)] CT chest with expiratory views showed air trapping in the left upper lobe and ground glass opacities, consistent with constrictive bronchiolitis. 6 months prior, she was diagnosed with abdominal grade 1 follicular lymphoma, treated with Bendamustine and Rituximab. One month into treatment, she developed a lichenoid rash involving the oro-gential mucosa and erythematous papular skin eruptions. Her eruptions and constrictive bronchiolitis were consistent with PAMS with pulmonary involvement. The rash improved with oral steroids and topical therapies, but her pulmonary symptoms did not. The likelihood of progression was low, so lymphoma was not a contraindication for lung transplantation. To ensure complete metabolic remission, she was further treated with R-CHOP and maintained on Rituximab. During transplant evaluation, FEV1 was 30% with NYHA class II, Karnofsky score 60 and she required 4L oxygen. She grew mycobacterium abscessus subspecies abscessus on 3 different sets of induced sputum. Secondary to radiographic findings consistent with NTM-PD (bronchial wall thickening and mucoid impaction) and pending lung transplant, she was treated with omadacycline, tedizolid, amikacin and clofazimine until sputum culture negativity (3-months). She underwent lung transplantation and received pre-operative Mycophenolate and Methylprednisolone without induction immunosuppression. Post-operatively she was started on Tacrolimus, Mycophenolate Mofetil and Prednisone. M. Abscessus therapy continued for 2 months post-transplant. At 6 months post-transplant, she is well, and PFTs are improving without evidence of organ rejection, lymphoma recurrence, or M. abscessus infection. Discussion: Pulmonary involvement in PAMS is associated with high mortality and is not reversed by treatment of the neoplasm, due to non-reversible destruction of small airways. The only disease modifying therapy is lung transplant. Her lymphoma recurrence risk was very low after 2 years of remission following initial treatment, and as her lymphoma was not associated with immunosuppression, post-transplant immunosuppression likely does not increase risk of recurrence. Additionally, while mycobacterium abscessus poses significant risks, intensive treatment in the peri-transplant period can help allow for safe transplantation.
Differences in COVID-19 Vaccination Behaviors Among Adults With Versus Without Chronic Lower Respiratory Diseases: The C4R Study
Lawin, K., Norwood, Arnita F. , Stukovsky, Karen Hinckley , Elkind, Mitchell S, Ortega, Victor E. , Lopez, Victor , Zhang, Ying , Fretts, Amanda M. , Oelsner, Elizabeth C. , Oelsner, Elizabeth C , Wang, Timothy C. , Lawin, K., Kucharska‐Newton, Anna , Demmer, Ryan T. , Jacobs, David R. , Regan, Elizabeth Anne , Lee, Joyce , Xanthakis, Vanessa , Isasi, Carmen R. , Kanaya, Alka M , Post, Wendy S. , Howard, Virginia J. , Lopez, V., Balte, Pallavi

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A7464-A7464

10.1164/ajrccm.2025.211.abstracts.a7464 Get It

Abstract RATIONALE: Chronic lower respiratory diseases (CLRD) confer higher risks from respiratory viral infections, hence CLRD patients are prioritized for influenza, pneumococcal, and COVID-19 vaccination. Nonetheless, vaccine deferral and declination remain common. Given that COVID-19 vaccination is particularly polarizing, and attitudes toward it may differ from other vaccines, we assessed COVID-19 vaccination behaviors and attitudes in adults with versus without CLRD and/or smoking history, which is strongly associated with CLRD risk. METHODS: We pooled data from 10 cohorts participating in the Collaborative Cohort of Cohorts for COVID-19 Research (C4R) that collected pre-pandemic data on self-reported physician diagnosis of asthma or COPD. C4R assessed COVID-19 vaccination status through three waves of standardized questionnaires (2020-2022, 2021-2023, 2023-2024). Prompt COVID-19 vaccination was defined as self-report of receiving at least one COVID-19 vaccine by May 1, 2021. Cumulative COVID-19 vaccine count was self-reported on the Wave 3 Questionnaire. Vaccine attitudes and receipt of influenza and/or pneumococcal vaccines were self-reported on the Wave 1 or 2 Questionnaire. Age-adjusted Poisson regression was used to test associations of vaccination behaviors with CLRD and smoking status at the most recent pre-pandemic exam. RESULTS: Of 20,034 participants (pre-pandemic COPD, 9.3%; asthma, 11.7%; current smoking, 13.4%; former smoking, 36.3%), 64.2% reported prompt COVID-19 vaccination. Among the subset of 10,626 participants completing the Wave 3 Questionnaire in 2023-24, the median COVID-19 vaccine count was 3 (Q1:2, Q3:4). Compared to participants without CLRD, prompt vaccination was more likely in those with asthma (RR=1.04, 95%CI:1.01-1.07, p=0.008) and less likely with COPD (RR=0.94, 95%CI:0.91-0.98, p=0.001), but there were no differences in doses for asthma and COPD. Compared to never smokers, former smoking participants were more likely to receive prompt vaccination (RR=1.11, 95%CI:1.08-1.13, p<0.0001) and more vaccine doses (RR=1.03, 95%CI:1.01-1.05, p=0.015); conversely, current smoking was inversely associated with prompt vaccination (RR=0.94, 95%CI:0.91-0.97, p=0.001) and was associated with fewer doses (RR=0.93, 95%CI:0.89-0.96, p<0.0001). Participants with CLRD versus without CLRD were more likely to report receiving influenza and pneumococcal vaccines, but they were more likely to believe that vaccines are unsafe or ineffective (figure). CONCLUSIONS: COPD was associated with lower likelihood of prompt COVID-19 vaccination. Current smoking was associated with both lower likelihood of prompt COVID-19 vaccination and a lower number of COVID-19 vaccine doses by 2023-24. These associations may be partly attributed to negative vaccine attitudes and beliefs. How the COVID-19 pandemic may have influenced vaccine behaviors and attitudes merits additional study.
Changes in Lung Function in Patients With Non-cystic Fibrosis Bronchiectasis Who Did or Did Not Have On-study Pulmonary Exacerbations: An Analysis of the ASPEN Trial
Loebinger, M.R., Aksamit, Timothy R. , Lauterio, M., Fucile, Sebastian, Teper, Ariel, Fernandez, C., Mange, Kevin C., Shih, Vivian H. , Chalmers, J.D., Metersky, Mark L. , Addrizzo‐Harris, Doreen , Fernandez, C.

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A7415-A7415

10.1164/ajrccm.2025.211.abstracts.a7415 Get It

Abstract Rationale Non-cystic fibrosis bronchiectasis (hereafter bronchiectasis) is a chronic and progressive respiratory disease. Neutrophilic inflammation plays a key role in the pathophysiology of bronchiectasis. Neutrophil serine proteases (NSPs), especially neutrophil elastase, have been associated with disease progression and poorer clinical outcomes. Brensocatib, an oral, selective, competitive, and reversible inhibitor of dipeptidyl peptidase 1, prevents activation of NSPs. In the phase 3, randomized, double-blind ASPEN trial (NCT04594369), treatment with once-daily brensocatib 10- or 25-mg significantly reduced the annualized rate of adjudicated pulmonary exacerbations over 52 weeks vs placebo; brensocatib 25-mg also significantly reduced lung function decline and improved patient-reported symptoms. Here, we further evaluate the impact of brensocatib on lung function in patients with bronchiectasis. Methods ASPEN enrolled patients with bronchiectasis and a history of pulmonary exacerbations in the 12 months prior to screening (adults [18-85 years], ≥2; adolescents [12-<18 years], ≥1). Patients were randomized to receive once-daily brensocatib (10- or 25-mg) or matching placebo for 52 weeks (adults, 1:1:1; adolescents, 2:2:1). Post-hoc analyses were conducted to evaluate the extent of lung function response to treatment, as measured by change from baseline in post-bronchodilator (BD) forced expiratory volume in 1 second (FEV1) over the 52-week treatment period in patients who did vs did not have ≥1 on-study pulmonary exacerbation, and the level of change in post-BD FEV1 and forced vital capacity (FVC) at week 52. Results A total of 583 patients received brensocatib 10-mg, 575 received brensocatib 25-mg, and 563 received placebo. Overall, a greater decline in FEV1 was observed among patients with ≥1 on-study pulmonary exacerbation vs those without. Treatment with brensocatib 10-mg or 25-mg led to less FEV1 decline at week 52 vs placebo for patients regardless of on-study exacerbation (no exacerbation: -42mL, -8mL, vs -48mL; ≥1 exacerbation: -59mL, -41mL, vs -70mL, for 10-mg, 25-mg brensocatib and placebo, respectively [Figure]). In the overall population, no change or an improvement (≥0 mL difference vs baseline) in post-BD FEV1 at week 52 was observed in 38.7%, 45.4%, and 31.2% of patients in the brensocatib 10-mg, 25-mg, and placebo groups, respectively. Similar impacts of brensocatib were observed in FVC (no change or improvement, 10-mg: 41.3%; 25-mg: 48.9%; placebo: 31.8%). Conclusions Overall, greater lung function decline was observed in patients who had on-study pulmonary exacerbations vs those who did not. Brensocatib 25-mg reduced lung function decline vs placebo regardless of whether patients had on-study exacerbations, consistent with overall ASPEN results.
Emergence of the Alveolar Epithelium: A Matter of Time and Tension
Ali, Gibran , Gibbard, D., Ghelfi, Elisa , Cai, Jiyang , Sawhney, Amarpreet S., Deskin, B. , Guo, Mingzhou , Haber, Adam L. , Bungum, Aaron O., Schrandt, Amy, Brownfield, Douglas , Sawhney, A., Han, Yueh‐Ying

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A7408-A7408

10.1164/ajrccm.2025.211.abstracts.a7408 Get It

Abstract RATIONALE: Alveoli form late in development and, for first breath, alveolar type 1 (AT1) as well as AT2 epithelial cell types must be functional. While prior studies have mapped the cellular and transcriptional programs underlying this process and identified AT fate inductive cues, questions remain as to the timing and regulation of their emergence. Thus, we sought to identify when, where, and how AT2 cells first arise and motivated by recent work in embryonic stem cells, we investigated whether the biophysical parameter cell membrane tension (CMT) plays a role. METHODS: Single-cell RNA-sequencing (scRNAseq) datasets sampling mouse lung development were processed using cluster correlation, velocity, and gene ontology analysis. Marker expression and AT2 morphology was assessed by immunostaining, and their migration confirmed by time-lapse confocal microscopy on embryonic precision-cut lung slices (PCLS). CMT was measured via optical tweezers (OT) on isolated cells as well as fluorescence lifetime (FLIM) on organoids and PCLS. Progenitors (E15.5) and AT2s (E16.5- >PN50) were isolated from distal region of the mouse lung, as well as human AT2s recently isolated, expanded, and banked in Mayo Clinic's recently established patient lung cell biorepository. CMT was raised using methyl-β-cyclodextran (MBCD) or polyethylene glycol (PEG). Small molecules CHIR and ICG-001 were used in culture to raise and lower β-catenin levels, respectively. Fluorescently labeled mesenchymal cells were isolated, expanded, and added to organoids in suspension for co-association experiments. RESULTS: No evidence of distal progenitors selecting either AT fate was found until E16.5, at which time we identified a distinct nascent AT2 (nAT2) state that ontology analysis detects upregulation of single-cell migration genes. Resistin-like molecule alpha (RELM-α), a type 2 inflammation regulator, labels nAT2s – which first individually emerged around E16.5 (although instances exist at E15.5) at intermediate zones between the branch tips and stalks of the distal epithelium. Following molecular emergence, we observed nAT2s extruded basally and can subsequently interact with nearby but anatomically distinct lumens, a behavior we provisionally name interlumenal junctioning and whose dynamics we validated by timelapse microscopy. Regarding CMT, we found its reduction in distal progenitors occurs prior to, and is required for, differentiation. We observed CMT reduction is sensitive to the manner of organoid culture, with on top culture resulting in more reduction and differentiation. Finally, we observed CMT is regulated cell-intrinsically via the adaptor protein β-catenin, as well as -extrinsically through osmotic (via PEG) or mesenchymal cell interactions, both of which reduce membrane fluidity.
Differences in Airway Epithelial Gene Expression in Resilient vs Non-resilient Smokers
Oh, Anna , Niederhuber, Matthew J. , Jones, Corbin D. , Brennan, Tara A., Currin, Kevin W., Kennedy, Sarah , Christenson, S., Bon, Jessica , Comellas, Alejandro P. , Cooper, C.B., Hansel, N.N., Kaner, R.J. , Marchetti, Nathaniel , Onofrei, C.D., Ortega, Victor E. , Paine, Robert , Woodruff, P., Investigators, SPIROMICS, Christenson, Stephanie A. , Comellas, Alejandro P , Christenson, Stephanie A , Oh, A., Liu, Heng , Kennedy, S., Couper, David , Barjaktarević, Igor , Barr, R. Graham , Bowler, Russell P. , Cooper, C.B. , Han, Mingyuan , Krishnan, Jerry A , Martínez, Fernando J. , Wells, J. Michael

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A7375-A7375

10.1164/ajrccm.2025.211.abstracts.a7375 Get It

Abstract Introduction Resilient smokers, who maintain respiratory health despite smoking, remain poorly characterized. Airway epithelial cell gene expression in resilient smokers can provide insight into mechanisms and pathways that may protect smokers from developing smoking-related lung disease. The objective of this study is to identify genes and potential pathways associated with lung-related resilience. Methods Resilient smokers were defined based on a previously published multi-dimensional definition which includes the absence of: 1) spirometric airflow limitation, 2) symptoms (cough/sputum, dyspnea), 3) radiographic (HRCT) abnormalities, 4) exacerbations, and 5) an accelerated FEV1 decline. “Non-resilient” smokers had preserved spirometry but showed abnormalities in at least one domain of resilience. We analyzed airway epithelial brush samples from 21 resilient and 34 non-resilient smokers from SPIROMICS. Differential gene expression was performed using DESeq2 package in R, which estimates differential expression using generalized linear models. We adjusted for sequencing batch, age (continuous), race, gender, and current smoking status. While controlling for these covariates we evaluated differential gene expression between resilient and non-resilient smokers, the interaction between resilience and smoking status, and in each sub-category of resilient (absence of symptoms, radiographic abnormalities, exacerbations, and accelerated decline in FEV1). Results We identified 98 genes that were differentially expressed (FDR ≤0.1) when comparing resilient to non-resilient smokers, 20 of those genes were up regulated in resilient smokers (Figure 1). Notable genes included cadherin-12 (CDH12), aspartate beta-hydroxylase (ASPH), and protein kinase AMP-activated alpha 2 (PRKAA2). CDH12 is involved in cell adhesion and epithelial integrity. ASPH influences cell adhesion and signaling. PRKAA2 plays role in cellular homeostasis and stress response, which may be altered in non-resilient smokers, affecting cellular metabolism and inflammation. BPI folding containing family A member (BPIFA1) was significantly associated with smoking status in the interaction analysis, suggesting its role in modulating the impact of smoking on resilience. BPIFA1 has anti-microbial properties, regulates immune responses, and contributes mucosal surface protection. Sub-category analysis identified 17 genes associated with resilience to symptoms and 2 genes related to physiologic resilience (FEV1 decline), though no significant genes were associated with radiographic or exacerbation resilience. Conclusion Differential gene expression of airway epithelial cells identified distinct expression patterns between resilient and non-resilient smokers. Specifically, genes associated with epithelial cell adhesion, signaling, and cellular homeostasis were up regulated in resilient smokers. These findings suggest that resilient smokers may have transcriptomic profiles and potential mechanisms that mitigate the effects of cigarette smoke.
Impact of Home-Based Pulmonary Rehabilitation in Fibrotic Interstitial Lung Disease
Roy, M., Moua, Teng , Moon, Ji‐Yong , Roy, M.

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A7292-A7292

10.1164/ajrccm.2025.211.abstracts.a7292 Get It

Abstract Rationale: Fibrotic interstitial lung diseases (f-ILDs) often lead to increased dyspnea and decreased physical activity, negatively impacting patient quality of life. While center-based pulmonary rehabilitation (PR) provides known benefits, access and adherence may be limited. This study investigates the implementation of a home-based pulmonary rehabilitation program with telephonic health coaching to improve physical activity and respiratory-related quality of life (RR-QOL) over 12 weeks. Methods: This prospective, single-center, non-randomized study enrolled patients with various f-ILD subtypes and severities over two years. Participants engaged in video-based exercises (25 minutes/day, 6 days per week) with weekly telephonic health coaching. Primary outcomes included changes in average daily steps, dyspnea (modified Medical Research Council (mMRC)), and self-reported RR-QOL (Chronic Respiratory Questionnaire (CRQ)- Physical and Emotional Summary domain scores). Minimal Clinically Important Differences (MCID) for study endpoints were defined as ≥600 steps per day, 1-point change in mMRC, and 0.5-point change in CRQ Physical and Emotional Summary scores, used to stratify patient responses to intervention as improved, stable, or worsened. Pre- and post-intervention summary results were compared using paired two-sample t-tests. The percentage of patients reaching MCID thresholds for improvement in primary endpoints was also reported. Results: 88 patients completed the program (mean age 70.2 years, 54% male, and mean FVC 66.9%). Mean CRQ Physical Summary scores improved from baseline 4.09 to 4.35 (mean improvement of 0.26 with 95% CI [0.06, 0.46]). 35% of patients achieved MCID change in the CRQ Physical Summary score, 34% in the CRQ Emotional score, and 22% in mMRC. Although 24% of patients increased their daily steps by 600 or more, average daily steps declined from 7,594 to 7,103 (mean decrease of 492 with 95% CI [101, 883]). When stratified by outcome responses to intervention (improved, stable, or worsened), lower baseline DLCO% was associated with decreased CRQ Physical Summary Scores and daily steps. Conclusion: Home-based PR may improve self-reported quality of life in f-ILD patients, as evidenced by improved CRQ Physical Summary scores. DLCO% may be associated with poorer response to PR intervention, as lower values were associated with declines in CRQ Physical Summary scores and daily steps. These findings support the potential utility of home-based rehabilitation and customizing individual strategies according to baseline characteristics and background disease progression.
Baseline Dyspnea Associated With Risk for Severe Features of Bronchiectasis Phenotype in the US Bronchiectasis and Nontuberculous Mycobacterium Research Registry
Ignatius, Elisa H. , Aksamit, Timothy R. , Geyer, A, Richards, Cathy, Winthrop, K.L., Yohannes, Abebaw Mengistu , Brunton, Amanda E. , Choate, Radmila , Maselli, Diego J , Swenson, Colin , Richards, C.J., Solomon, George M

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A7282-A7282

10.1164/ajrccm.2025.211.abstracts.a7282 Get It

Abstract Introduction Persistent dyspnea increases the risk of disability and impairs quality of life in older patients with bronchiectasis. The impact of dyspnea and fatigue on patients with bronchiectasis in long term follow-up has not been adequately established. We sought to determine if fatigue and higher-grade dyspnea are associated with worse clinical outcomes in 5-years of longitudinal follow-up. Methods We analyzed data collected from a prospective cohort of adult patients with bronchiectasis enrolled in the US Bronchiectasis and Nontuberculous Mycobacteria Research Registry. Patients with a modified Medical Research Council (mMRC) dyspnea score collected at baseline and during 3-5 years of follow-up were included and stratified as mMRC<2 versus mMRC ≥2. Kruskal-Wallis, independent sample t-tests and chi-square tests were used to test the differences in medians and means for continuous variables and associations between categorical variables, respectively, between the baseline mMRC groups and bronchiectasis severity index (BSI) components at follow-up. A multivariable logistic regression analysis was performed to determine the association between dyspnea and clinical outcomes (exacerbations and hospitalizations) at follow-up. Results 1185 adult patients with bronchiectasis met the inclusion criteria. The median age (interquartile range) was 76 (68 to 83) years. At baseline, patients with mMRC ≥2 had a higher proportion of co-existing diagnoses such as asthma, chronic obstructive pulmonary disease (COPD), otitis/rhinosinusitis, rheumatologic disease, and pneumonia compared to patients with mMRC <2 (all p<0.05, data not shown). Furthermore, patients with mMRC > 2 compared to patients with mMRC <2 had higher prevalence of fatigue, acute exacerbations and pulmonary related hospitalizations, and lower mean percentage predicted forced expiratory volume in one second (FEV1) at follow-up (all p< 0.05) (Table 1). Interestingly, body mass index was slightly higher among those with baseline mMRC ≥2 compared to mMRC <2 (p=0.02). Among those with mMRC ≥2 at both baseline and follow-up (n=67, 42%), the odds of having ≥1 exacerbation was 2.4 times higher (odds ratio [OR] 2.45, 95% confidence interval [CI] 1.45-4.1) and 2.8 times higher for ≥1 hospitalization (OR 2.8, 95% CI 1.45-5.2) during follow-up after adjusting for fatigue. Conclusion Elevated dyspnea was associated with a greater proportion of patients with bronchiectasis exhibiting acute exacerbations and pulmonary related hospitalizations and lower lung function during follow-up. Research is still needed to understand the causes (drivers) of dyspnea to implement better treatment strategies and reduce adverse outcomes in bronchiectasis patients.
Impacts of “Race-neutral" GLI-Global Prediction Equations in Occupational Health
Townsend, Mary C., Harber, Philip , Cowl, Clayton T.

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A7202-A7202

10.1164/ajrccm.2025.211.abstracts.a7202 Get It

Abstract RATIONALE: The American Thoracic Society (ATS) recently recommended using “race-neutral” GLI-Global prediction equations to interpret spirometry results. However, the unintended consequences for workers have not been fully evaluated. METHODS: We analyzed the impact of adopting GLI-Global on 24 hypothetical subjects, using on-line calculators to examine the effects on 1) larger vs. smaller predicted values; 2) Black, Southeast Asian, Northeast Asian, and White races; and 3) 80%, 100%, and 120% of race-specific predicted forced vital capacity (FVC). RESULTS: Race-specific predicted FVCs decline by group: White > NE Asian > SE Asian > Black, with a difference of 0.84 L between Blacks and Whites. GLI-Global Predicteds are midway between Blacks’ and Whites’. Workers at 80% of race-specific Predicted change the most when GLI-Global is employed: Blacks and SE Asians show declining %Predicted values and Z-scores and an increase in FVCs<LLN, while Whites and NE Asians show increasing %Predicted and Z-scores and a decrease in FVCs<LLN. CONCLUSIONS: Choice of prediction equation for use in occupational health practice differentially affects individuals in several groups: a) When fixed criteria are used for job placement and retention decisions, Black and SE Asian persons may be particularly adversely affected, while Whites and NE Asians will more likely exceed the fixed criteria; b) When fixed criteria are used for disability decisions, Black and SE Asian persons may look increasingly disabled, while White and NE Asian persons may now fail to qualify for disability; and c) Disparate effects are most prominent for persons with lung function measures in the lower portion of the normal range. Since occupational criteria are unlikely to change quickly, clinicians and policymakers should consider the real-world implications of mandating or recommending specific equations.
Deterioration Index Correlated With Outcomes in Patients With Rapid Response Team Activations
Wanberg, Erik J. , Friesen, Joelle N. , Allman, Ava-Ann, Allman, A., Moraes, Alice Gallo de

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A7190-A7190

10.1164/ajrccm.2025.211.abstracts.a7190 Get It

Abstract Rationale: The Deterioration Index (DTI) may serve as a crucial tool for predicting adverse patient outcomes; however, there is a paucity of literature attempting to externally validate this tool in specific clinical scenarios. In this study, we analyzed the relationship between DTI scores during rapid response team (RRT) activations and subsequent ICU transfer, initiation of goals of care (GOC) conversations, and 90-day mortality. Methods: This was a retrospective single-center review of adult patients who had an RRT activation while hospitalized between January 1, 2023 and December 31, 2023. This study was approved by our hospital institutional review board. Deterioration scores (0-100) were recorded every 15 minutes during the RRT event, and the highest score of each encounter was selected for analysis. The primary outcome was transfer to the ICU as a direct result of the RRT activation. Secondary outcomes included GOC discussions following RRT activation and 90-day mortality. GOC discussions, defined as physician-led conversations that specifically addressed code status, treatment priorities, or broader goals of care, met criteria only if initiated within 72 hours of the analyzed RRT activation. Logistic regression was used to assess the relationship between DTI scores during RRT activations and the aforementioned variables. Results: A total of 1643 patients were included in the analysis. For every 1-point increase in the deterioration score, the odds of ICU transfer increased by 2.7% (OR: 1.027, CI: 1.021-1.034, p<0.0001), the odds of a goals of care discussion within 72 hours increased by 3.3% (OR: 1.033, CI: 1.025-1.040, p<0.0001), and the likelihood of mortality within 90 days increased by 2.6% (OR: 1.026, CI: 1.019-1.033, p<0.0001). Conclusion: Our findings contribute to external validation of DTI predictive value during RRT events. DTI scores were associated with key clinical outcomes, including ICU transfer and 90-day mortality. There was also an association between DTI scores and the likelihood of physician-led GOC discussions, suggesting that DTI may demonstrate predictive value not only of patient outcomes, but also the likelihood of specific non-medical physician actions. Further validation of these scores in prospective studies, specifically in the context of acute decompensation events, could help facilitate the integration of DTI-based RRT interventions into routine hospital practice.